These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 39241495)

  • 1. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.
    Rugo HS; Oliveira M; Howell SJ; Dalenc F; Cortes J; Gomez HL; Hu X; Jhaveri KL; Krivorotko P; Loibl S; Morales Murillo S; Nowecki Z; Okera M; Park YH; Sohn J; Toi M; Iwata H; Yousef S; Zhukova L; Logan J; Twomey K; Khatun M; D'Cruz CM; Turner NC
    ESMO Open; 2024 Sep; 9(9):103697. PubMed ID: 39241495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
    Oliveira M; Rugo HS; Howell SJ; Dalenc F; Cortes J; Gomez HL; Hu X; Toi M; Jhaveri K; Krivorotko P; Loibl S; Morales Murillo S; Okera M; Nowecki Z; Park YH; Sohn JH; Tokunaga E; Yousef S; Zhukova L; Fulford M; Andrews H; Wadsworth I; D'Cruz C; Turner NC;
    Lancet Oncol; 2024 Sep; 25(9):1231-1244. PubMed ID: 39214106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
    Howell SJ; Casbard A; Carucci M; Ingarfield K; Butler R; Morgan S; Meissner M; Bale C; Bezecny P; Moon S; Twelves C; Venkitaraman R; Waters S; de Bruin EC; Schiavon G; Foxley A; Jones RH
    Lancet Oncol; 2022 Jul; 23(7):851-864. PubMed ID: 35671774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
    Jones RH; Casbard A; Carucci M; Cox C; Butler R; Alchami F; Madden TA; Bale C; Bezecny P; Joffe J; Moon S; Twelves C; Venkitaraman R; Waters S; Foxley A; Howell SJ
    Lancet Oncol; 2020 Mar; 21(3):345-357. PubMed ID: 32035020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
    Turner NC; Oliveira M; Howell SJ; Dalenc F; Cortes J; Gomez Moreno HL; Hu X; Jhaveri K; Krivorotko P; Loibl S; Morales Murillo S; Okera M; Park YH; Sohn J; Toi M; Tokunaga E; Yousef S; Zhukova L; de Bruin EC; Grinsted L; Schiavon G; Foxley A; Rugo HS;
    N Engl J Med; 2023 Jun; 388(22):2058-2070. PubMed ID: 37256976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with
    Smyth LM; Tamura K; Oliveira M; Ciruelos EM; Mayer IA; Sablin MP; Biganzoli L; Ambrose HJ; Ashton J; Barnicle A; Cashell DD; Corcoran C; de Bruin EC; Foxley A; Hauser J; Lindemann JPO; Maudsley R; McEwen R; Moschetta M; Pass M; Rowlands V; Schiavon G; Banerji U; Scaltriti M; Taylor BS; Chandarlapaty S; Baselga J; Hyman DM
    Clin Cancer Res; 2020 Aug; 26(15):3947-3957. PubMed ID: 32312891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
    Rugo HS; André F; Yamashita T; Cerda H; Toledano I; Stemmer SM; Jurado JC; Juric D; Mayer I; Ciruelos EM; Iwata H; Conte P; Campone M; Wilke C; Mills D; Lteif A; Miller M; Gaudenzi F; Loibl S
    Ann Oncol; 2020 Aug; 31(8):1001-1010. PubMed ID: 32416251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "The emerging role of capivasertib in breast cancer".
    Andrikopoulou A; Chatzinikolaou S; Panourgias E; Kaparelou M; Liontos M; Dimopoulos MA; Zagouri F
    Breast; 2022 Jun; 63():157-167. PubMed ID: 35398754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
    Turner NC; Alarcón E; Armstrong AC; Philco M; López Chuken YA; Sablin MP; Tamura K; Gómez Villanueva A; Pérez-Fidalgo JA; Cheung SYA; Corcoran C; Cullberg M; Davies BR; de Bruin EC; Foxley A; Lindemann JPO; Maudsley R; Moschetta M; Outhwaite E; Pass M; Rugman P; Schiavon G; Oliveira M
    Ann Oncol; 2019 May; 30(5):774-780. PubMed ID: 30860570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer.
    Luboff AJ; DeRemer DL
    Ann Pharmacother; 2024 Dec; 58(12):1229-1237. PubMed ID: 38566315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.
    Turner NC; Oliveira M; Howell SJ; Dalenc F; Cortés J; Gomez HL; Hu X; Jhaveri K; Krivorotko P; Loibl S; Murillo SM; Park YH; Sohn JH; Toi M; Tokunaga E; Yousef S; Zhukova L; de Bruin E; Grinsted L; Schiavon G; Foxley A; Rugo HS
    Future Oncol; 2024; 20(37):2901-2913. PubMed ID: 39283299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID).
    Crabb SJ; Griffiths G; Marwood E; Dunkley D; Downs N; Martin K; Light M; Northey J; Wilding S; Whitehead A; Shaw E; Birtle AJ; Bahl A; Elliott T; Westbury C; Sundar S; Robinson A; Jagdev S; Kumar S; Rooney C; Salinas-Souza C; Stephens C; Khoo V; Jones RJ
    J Clin Oncol; 2021 Jan; 39(3):190-201. PubMed ID: 33326257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.
    Tokunaga E; Iwata H; Itoh M; Taira T; Toyama T; Mizuno T; Osaki A; Yanagita Y; Nakamura S; Nakamura R; Sambe T; Ozaki T; Schiavon G; Howell SJ; Toi M
    Breast Cancer; 2024 Oct; ():. PubMed ID: 39379782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
    Rugo HS; Huober J; García-Sáenz JA; Masuda N; Sohn JH; Andre VAM; Barriga S; Cox J; Goetz M
    Oncologist; 2021 Jan; 26(1):e53-e65. PubMed ID: 32955138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
    Kornblum N; Zhao F; Manola J; Klein P; Ramaswamy B; Brufsky A; Stella PJ; Burnette B; Telli M; Makower DF; Cheema P; Truica CI; Wolff AC; Soori GS; Haley B; Wassenaar TR; Goldstein LJ; Miller KD; Sparano JA
    J Clin Oncol; 2018 Jun; 36(16):1556-1563. PubMed ID: 29664714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpelisib for
    André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
    N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capivasertib Doubles PFS in Some Breast Cancers.
    Cancer Discov; 2023 Feb; 13(2):250. PubMed ID: 36508589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
    Campone M; Im SA; Iwata H; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Cortés J; De Laurentiis M; Arteaga CL; Jiang Z; Jonat W; Le Mouhaër S; Sankaran B; Bourdeau L; El-Hashimy M; Sellami D; Baselga J
    Eur J Cancer; 2018 Nov; 103():147-154. PubMed ID: 30241001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capivasertib in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative advanced breast cancer.
    Qureshi Z; Altaf F; Khanzada M; Zaheer Z; Fatima E; Bakhtiar M
    Curr Probl Cancer; 2024 Aug; 51():101114. PubMed ID: 38959565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.